Committees and Investigators
BLGSP Steering Committee
Riccardo Dalla-Favera, M.D. Director of the Institute for Cancer Genetics, Uris Professor of Clinical Medicine, Professor of Pathology and Cell Biology, Genetics and Development, Microbiology and Immunology, Columbia University
Daniela S. Gerhard, Ph.D. Director OCG,CCG, Associate Director of Precision Oncology at NCI
John D. Irvin, M.D., Ph.D. Foundation Executive Director
Ariela Noy, MD Member and Attending Physcian Hematology Division, Lymphoma Service, Memorial Sloan-Kettering Cancer Center; Lymphoma Working Group Chair, AIDS Malignancy Consortium; and Professor of Medicine Weill Cornell Medical College
Louis Staudt, M.D., Ph.D. Chief, Lymphoid Malignancies Branch NIH, NIH Distinguished Investigator, and Director, NCI Center for Cancer Genomics
Jean Claude Zenklusen Director of the Cancer Genome Atlas Program, National Cancer Institute (Dr. Zenklusen assumed Dr. Gerhard's responsibilities for the BLGSP in September, 2021)
Pathology Review Committee
Timothy C. Greiner, MD Professor and director of Hematopathology, Amelia and Austin Vickery Professor of Pathology, University of Nebraska Medical Center
Nancy Lee Harris, M.D. Austin L. Vickery, Jr. Professor of Pathology at Massachusetts General Hospital (MGH) and the Harvard Medical School; Editor of the Case Records of MGH for the New England Journal of Medicine
Elaine S. Jaffe, M.D. Chief, Hematopathology Section, National Cancer Institute
Steven H. Swerdlow, M.D. Professor of Pathology, Director of Hematopathology, Univ. of Pittsburg School of Medicine
BLGSP Study Investigators/Tissue Source Sites
Jeremy Abramson, MD Director of the Lymphoma Program, Jon and JoAnn Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center; Assistant Professor of Medicine at the Harvard Medical School
Corey Casper, M.D., M.P.H. Chief Executive Officer, Access To Advanced Health Institute (AAHI); Clinical Professor of Medicine and Global Health, University of Washington; Affiliate Member, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
Alina Gerrie, M.D., MPH, FRCPC Assistant Professor, Hematology and Medical Oncology, Univ. British Columbia, Lymphoma Tumor Group, BC Cancer
Sam Mbulaiteye, M.D. Senior Investigator, Infectious and Immunoepidemiology Branch, National Cancer Institute; Principal Investigator of the EMBLEM Study
Charles G. Mullighan, MBBS (Hons), MSC, MD Deputy Director Comprehensive Cancer Center, Co-Leader of the Hematological Malignancies Program, Member in the Department of Pathology, St. Jude Children’s Research Hospital
Ariela Noy, MD Member and Attending Physcian Hematology Division, Lymphoma Service, Memorial Sloan-Kettering Cancer Center; Lymphoma Working Group Chair, AIDS Malignancy Consortium; and Professor of Medicine Weill Cornell Medical College
David Scott, MBChB, PhD, FRACP, FRCPA Associate Professor, Deputy Head at Department of Lymphoid Cancer Research at Faculty of Medicine, Univ. of British Columbia, Clinical Scientist, BC Cancer
Wyndham H. Wilson, M.D., Ph.D. Head, Lymphoma Therapeutics Section and Senior Investigator of the Lymphoid Malignancy Branch, National Cancer Institute
Nicholas B. Griner, Ph.D., resigned from his NCI position of BLGSP Scientific Program Manager and member of the Steering Committee, January, 2022.